Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
REHOVOT, Israel and HOBOKEN, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ:KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties. Within the first four years of the eight-year term, which begins in January 2024, Kedrion will purchase minimum quantities of KEDRAB with revenues to Kamada of approximately $180 million.
Related news for (KMDA)
- Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
- Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability
- Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®
- Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
- Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas